Amend 004 - Hepatitis B Adult and Pediatric Vaccine - GlaxoSmithKline Inc.

Contract number E60PH-22HEPB/001/PH

Amendment value : CAD 8,257,621.63

Solicitation number E60PH-22HEPB

Contract award date 2022/03/07

Expiry date 2025/03/31

Amendment date 2024/03/07

Amendment type

Amendment

Contract details

This contract was awarded to:

GlaxoSmithKline Inc.

Hepatitis B Adult and Pediatric Vaccine

Business address: 100 Milverton Drive Suite 800

Mississauga, Ontario, L5R 4H1

CA
Notice type: Request for Proposal
Contract instrument type: Contract
Language(s): English
,
French
Selection criteria: Lowest Price

View the full contract history for GlaxoSmithKline Inc..

Contract duration

The contract will be for a period of 36 month(s), from 2022/03/07 to 2025/03/31.

Total value of contract

This is the total value of this contract, which includes the initial contract value and the sum of all amendments.

CAD 21,595,100.80

Commodity - UNSPSC

51000000 - Drugs and Pharmaceutical Products

Trade agreements

Canada-European Union Comprehensive Economic and Trade Agreement (CETA)
Canada-Korea Free Trade Agreement (CKFTA)
Canada-UK Trade Continuity Agreement (Canada-UK TCA)
Canada-Chile Free Trade Agreement (CCFTA)
Canada-Honduras Free Trade Agreement
Canada-Peru Free Trade Agreement (CPFTA)
Canada-Colombia Free Trade Agreement
Canadian Free Trade Agreement (CFTA)
Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP)
World Trade Organization Agreement on Government Procurement (WTO GPA)
Canada-Panama Free Trade Agreement

Contact information

Contracting organization

Organization: Department of Public Works and Government Services (PSPC)
Address: 11 Laurier St, Phase III, Place du Portage

Gatineau, Quebec, K1A 0S5

Canada

Contracting authority: Meunier, Sherry (SPAC/PSPC)
Email: sherry.meunier@tpsgc-pwgsc.gc.ca

Buying organization(s)

Organization: Department of Public Works and Government Services (PSPC)
Address: 11 Laurier St, Phase III, Place du Portage

Gatineau, Quebec, K1A 0S5

Canada

Related notices

Amendments made to this contract (4) A total of 4 amendments have been made to this contract. Click to expand Click to collapse

This is a list of the amendments made to contract

E60PH-22HEPB/001/PH that is awarded to GlaxoSmithKline Inc..

List of amendments made to this contract. The columns are sortable in ascending and descending order.
Amendment number	Contract value	Award date
003	CAD 21 595 100.80	2022/03/07
002	CAD 21 595 100.80	2022/03/07
001	CAD 21 595 100.80	2022/03/07
000	CAD 21 595 100.80	2022/03/07

Tender notices (1) This contract has 1 related tender notices. Click to expand Click to collapse

List of related tender notices. The columns are sortable in ascending and descending order.
Title	Solicitation Number	Publication date	Closing date
Hepatitis B Adult and Pediatrics	E60PH-22HEPB/A	2022/01/06	2022/01/26

Contracts awarded (2) This contract has 2 related award notices. Click to expand Click to collapse

This is a list of other contracts that were awarded related to solicitation number E60PH-22HEPB. Click the link under “More details” to view the contract details.

List of related contracts awarded and their amendments. The columns are sortable in ascending and descending order.
Company name	Contract number	Amendment date	Award date	More details
GlaxoSmithKline Inc.	E60PH-22HEPB/001/PH	2024/03/07	2022/03/07	Viewthe details of contract E60PH-22HEPB/001/PH for GlaxoSmithKline Inc.
Merck Canada Inc.	E60PH-22HEPB/002/PH	2024/03/05	2022/03/07	Viewthe details of contract E60PH-22HEPB/002/PH for Merck Canada Inc.

Contract history (9) This contract has 9 related contracts. Click to expand Click to collapse

This is a list of other contracts that were awarded and their amendments. Click the link under “More details” to view the contract details.

List of other contracts awarded and their amendments. The columns are sortable in ascending and descending order.
Company name	Contract number	Amendment number	Award date	More details
Merck Canada Inc.	E60PH-22HEPB/002/PH	004	2022/03/07	Viewthe details of contract E60PH-22HEPB/002/PH for Merck Canada Inc.
Merck Canada Inc.	E60PH-22HEPB/002/PH	003	2022/03/07	Viewthe details of contract E60PH-22HEPB/002/PH for Merck Canada Inc.
GlaxoSmithKline Inc.	E60PH-22HEPB/001/PH	003	2022/03/07	Viewthe details of contract E60PH-22HEPB/001/PH for GlaxoSmithKline Inc.
MERCK CANADA INC.	E60PH-22HEPB/002/PH	002	2022/03/07	Viewthe details of contract E60PH-22HEPB/002/PH for MERCK CANADA INC.
GlaxoSmithKline Inc.	E60PH-22HEPB/001/PH	002	2022/03/07	Viewthe details of contract E60PH-22HEPB/001/PH for GlaxoSmithKline Inc.
MERCK CANADA INC.	E60PH-22HEPB/002/PH	001	2022/03/07	Viewthe details of contract E60PH-22HEPB/002/PH for MERCK CANADA INC.
GlaxoSmithKline Inc.	E60PH-22HEPB/001/PH	001	2022/03/07	Viewthe details of contract E60PH-22HEPB/001/PH for GlaxoSmithKline Inc.
MERCK CANADA INC.	E60PH-22HEPB/002/PH	000	2022/03/07	Viewthe details of contract E60PH-22HEPB/002/PH for MERCK CANADA INC.
GlaxoSmithKline Inc.	E60PH-22HEPB/001/PH	000	2022/03/07	Viewthe details of contract E60PH-22HEPB/001/PH for GlaxoSmithKline Inc.

Report a problem on this page